FDA Clears a New Class for Over-the-Counter Sleep Apnea Checks
Published Date: 10/30/2026
Rule
Summary
The FDA is officially classifying over-the-counter devices that check your risk for sleep apnea as Class II, meaning they have special safety rules but are easier to get to help more people. This change, effective October 30, 2026, makes these devices safer and more accessible without heavy red tape. If you make or use these devices, expect smoother approval and better access starting now!
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Easier Market Path for Device Makers via De Novo Predicate
Because FDA granted De Novo classification, this OTC sleep-apnea risk device can serve as a predicate for future devices, allowing other sponsors to use the less-burdensome 510(k) pathway instead of the more burdensome premarket approval route. FDA states this can reduce regulatory burdens and help other device makers bring similar devices to market more easily.
Premarket 510(k) Still Required for These Devices
FDA states that over-the-counter devices to assess risk of sleep apnea are subject to premarket notification requirements under section 510(k) of the Federal Food, Drug, and Cosmetic Act unless FDA exempts the device type under section 510(m). At this time, FDA has not exempted this device type, so manufacturers must submit a 510(k).
Detailed Special Controls for Safety and Usability
FDA requires specific special controls for these OTC devices, including clinical performance testing (with representative symptomatic and asymptomatic populations, subgroup analyses, and comparison to a clinical comparator), non-clinical performance testing (including noisy/missing data handling), electrical and electromagnetic safety, biocompatibility for skin-contacting parts, software verification/validation and hazard analysis (with specified documentation), human factors/usability testing (users must be able to use the device based only on directions and know when to seek care), and labeling that includes measurement descriptions, platform requirements, sensor data types, warnings, and a summary of clinical performance.
OTC Sleep-Apnea Risk Devices Reclassified to Class II
The FDA officially classified over-the-counter devices that assess risk of sleep apnea as Class II (special controls). This classification is effective October 30, 2026, and was applicable on February 6, 2024. The device type is defined at 21 CFR 868.2378 and is intended to notify users who have not been previously diagnosed of their risk of sleep apnea, but not to provide a standalone diagnosis or replace polysomnography.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-22181, Medical Devices; Anesthesiology Devices; Classification of the Spinal Imaging System for Neuraxial Procedures
The FDA is officially putting spinal imaging systems used in neuraxial procedures into Class II, meaning they’ll have special safety rules but less red tape than before. This change helps make sure these devices are safe and effective while speeding up patient access to new tech. The new classification took effect on October 30, 2026, but has been in place since January 19, 2024, so manufacturers should already be on board.
Next: 2026-22194, Medicare Program; CY 2027 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Acute Kidney Injury (AKI) Dialysis Payment, and ESRD Quality Incentive Program
Starting January 1, 2027, Medicare is updating how it pays for kidney dialysis treatments for people with End-Stage Renal Disease (ESRD) and those with Acute Kidney Injury (AKI). These changes include new payment rates and updated quality rules to make sure patients get the best care. If you’re a dialysis provider or patient, expect some shifts in payments and quality standards that aim to improve treatment and support innovation.